Why Whitehawk Therapeutics, Inc.’s (WHWK) Stock Is Down 6.37%
As of Tuesday, August 11, Whitehawk Therapeutics, Inc.’s WHWK share price has dipped by 6.37%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Commentary & Analysis
Why Whitehawk Therapeutics, Inc.’s (WHWK) Stock Is Up 8.82%
As of Thursday, August 06, Whitehawk Therapeutics, Inc.’s WHWK share price has surged by 8.82%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Whitehawk Therapeutics, Inc.’s (WHWK) Stock Is Down 7.57%
As of Tuesday, July 28, Whitehawk Therapeutics, Inc.’s WHWK share price has dipped by 7.57%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Whitehawk Therapeutics, Inc.’s (WHWK) Stock Is Down 6.27%
As of Wednesday, July 08, Whitehawk Therapeutics, Inc.’s WHWK share price has dipped by 6.27%, which has investors questioning if this is right time to buy.Michael Rose
Why Whitehawk Therapeutics, Inc.’s (WHWK) Stock Is Up 6.12%
As of Tuesday, June 30, Whitehawk Therapeutics, Inc.’s WHWK share price has surged by 6.12%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | WHWK | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $213.8 | $257.1 | 28% |
|
| Shares Out (Mil) | 82.9 | 54.0 | 58% |
|
| Institutional Ownership | 81.9% | 93.2% | 50% |
|
| Float (Mil) | 28.7 | 41.3 | 35% |
|
| Beta | 0.81 | 0.95 | 48% |
|
| Avg Daily Volume (000s) | 407 | 728 | 53% |
|
| Price Change (52-week) |
95.3% | 50.6% | 93% |
|
| Growth | WHWK | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (13.4%) | 12.8% | 4% |
|
| Net Income (5yr) | (42.5%) | (10.1%) | 9% |
|
| EPS (5yr) | 28.3% | 15.7% | 79 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.2% | (15.7%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 3 | |
| Current EPS | ($0.247) | ($0.965) | ($0.987) | |
| Month Ago EPS | ($0.247) | ($0.965) | ($0.987) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 1 | 1 | |
| Three Months Ago EPS | ($0.287) | ($1.153) | ($1.167) | |
| Year/Year Chg | 22.9% | 189.8% | 236.3% | |
| Financials | WHWK | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($80) | ($44) | 13% |
|
| EPS (TTM) | ($1.098) | ($1.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($69) | ($33) | 8% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $40 | $173 | 15% |
|
| Valuation | WHWK | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.17 | 2.52 | 30% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | WHWK | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.2% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (42.6%) | (47.7%) | 13% |
|
| ROE | (45.0%) | (54.9%) | 16% |
|
| Liabilities to Assets | 5.7% | 29.0% | 3% |
|
| F-Score | 1 | 3 | na |
|
Whitehawk Therapeutics, Inc. did not pass any screens on 9/30/2026.
